Let’s treat cancer smarter
Our goal: We are committed to make tumor-suppressor mutant cancer treatable.
Our vision: We are creating a powerful platform to develop first-in-class drugs by turning the promise of synthetic lethality into reality.
We will beat cancer at its own game
Targeting synthetic lethality
We leverage our unique technology to develop novel small molecule inhibitors that exploit synthetic lethal vulnerabilities in tumor-suppressor mutant cancers and establish epigenetic therapies for genetically-defined patient populations that lack therapeutic options.
We aim to promote better health of citizens
Our project and therapeutic opportunities:
Some of the most devastating tumors develop because they have lost tumor suppressor genes. These tumors are incredibly difficult to target, since their genomes constantly evolve. Even worse, for many tumors there are simply no cures. Thanks to major progress in the sequencing of human cancers, we have identified molecular Achilles heels – i.e. the essential engines that drive these tumor genome rearrangements. Importantly, using our key epigenetic technologies Eisbach Bio can target these tumors head-on.
Based on our unique screening and cellular platforms, we are developing first-in-class drugs that correct these disruptive changes within the tumor. We can do so in an extremely specific manner that spares non-cancer cells. Our therapies promise to transform the lives of many women and men for whom currently there are no cures. Eisbach will beat cancer at its own game.
Our groundbreaking approach:
Synthetic lethal vulnerabilities often center on epigenetic mechanisms, which alter gene activity and massively alter chromatin structure, rather than affecting the genes themselves. Current methods to study epigenetic gene regulation mainly use modified synthetic peptides or recombinant histone octamers, but these substrates do not correspond to the physiological substrate of those epigenetic enzymes, which is the nucleosome.
Thanks to our proprietary assay technology, which utilizes specifically modified nucleosomal substrates, and thanks to our in-depth insights into the allosteric regulation of our enzyme targets, we are in the unique position to assay the disease-relevant function and to demonstrate the activity of compounds that inhibit our cancer-essential enzymes.